A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF).

Principal Investigator

Dr Rachel Hoyles

Contact us

Email: samantha.chilcott@ndm.ox.ac.uk

IRAS number

1012881